Prestige Consumer Healthcare Reaffirms Growth Plan Amid Supply Constraints

Prestige Consumer Healthcare Inc. (PBH) maintained its growth strategy at a September 24, 2026, virtual small-cap conference, highlighting a year-over-year revenue decline of 4.3% in fiscal 2026 driven by supply constraints for its Clear Eyes sterile eye care line. Despite the setback, the company emphasized a strong free cash flow outlook, projecting $270 million or more for the current fiscal year, with a three-year cumulative target of approximately $900 million. Gross margins finished just under 56% in fiscal 2026 and are guided to exceed 57% annually, while EBITDA margins remained in the low-to-mid 30% range. Capital expenditures were expected to stay between 1% and 3% of sales, and the company’s cash tax rate was in the high teens.